Finally, we analyzed somatic mutations between different risk score subtypes and showed that the frequency of mutations in the KIT gene was higher in the low-risk group, while the frequency of RUNX1 and TP53 mutations was higher in the high-risk group, and these two genes have been included in AML treatment guidelines as molecules with poorer prognosis, but the somatic mutation frequencies were not significantly different between the two groups (Figure 6C, 6D). The gene discussed is TP53; the disease is acute myeloid leukemia.